1.1.1.62: 17beta-estradiol 17-dehydrogenase

This is an abbreviated version, for detailed information about 17beta-estradiol 17-dehydrogenase, go to the full flat file.

Reaction

17beta-estradiol
+
NAD(P)+
=
estrone
+
NAD(P)H
+
H+

Synonyms

(17beta-HSD) type 1, (17beta-HSD) type 2, 17-beta-HSD 2, 17-beta-hydroxysteroid dehydrogenase type 12, 17-beta-hydroxysteroid dehydrogenase type 2, 17-HOR, 17-HSD, 17beta HSD1, 17beta,20alpha-hydroxysteroid dehydrogenase, 17beta-estradiol dehydrogenase, 17beta-HSD, 17beta-HSD I, 17beta-HSD type 1, 17beta-HSD type 12, 17beta-HSD type 2, 17beta-HSD type 4, 17beta-HSD type 5, 17beta-HSD type 7, 17beta-HSD type 8, 17beta-HSD1, 17beta-HSD12, 17beta-HSD2, 17beta-HSD4, 17beta-HSD5, 17beta-HSD7 2, 17beta-HSDcl, 17beta-hydroxysteroid dehydrogenase, 17beta-hydroxysteroid dehydrogenase 4, 17beta-hydroxysteroid dehydrogenase type 1, 17beta-hydroxysteroid dehydrogenase type 12, 17beta-hydroxysteroid dehydrogenase type 2, 17beta-hydroxysteroid dehydrogenase type 4, 17beta-hydroxysteroid dehydrogenase type 5, 17beta-hydroxysteroid dehydrogenase type 6, 17beta-hydroxysteroid dehydrogenase type 7, 17beta-hydroxysteroid dehydrogenase type 8, 17beta-hydroxysteroid dehydrogenase type I, 17beta-hydroxysteroid dehydrogenase types 1, 17beta-hydroxysteroid dehydrogenases type 1, 17betaHSD, 17betaHSD1, 17betaHSD14, 17betaHSD6, 17HSD1, 20 alpha-hydroxysteroid dehydrogenase, 20-alpha-HSD, 20alpha-hydroxysteroid dehydrogenase, 3beta-HSD, 3beta-hydroxysteroid dehydrogenase, 3betaHSD, 7beta-HSD type 1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, dehydrogenase, estradiol 17beta-, E2DH, EDH, estradiol 17beta-dehydrogenase, estradiol dehydrogenase, estrogen 17-oxidoreductase, estrogenic 17beta-hydroxysteroid dehydrogenase, form 2 type 7 17beta-hydroxysteroid dehydrogenase, HSD17B1, HSD17B12, HSD17B2, HSD17B4, hydroxysteroid (17-beta) dehydrogenase 1, Ke6 protein, mf17beta-HSD12, microsomal 17-beta-hydroxysteroid dehydrogenase, More, oestradiol-17beta hydroxysteroid dehydrogenase, placental 17-beta-hydroxysteroid dehydrogenase, PRAP, PRL receptor associated protein, testicular 17-beta-hydroxysteroid dehydrogenase, type 1 17beta-HSD, type 1 17beta-hydroxysteroid dehydrogenase, type 12 17beta-HSD, type 12 17beta-hydroxysteroid dehydrogenase, type 7 17beta-hydroxysteroid dehydrogenase, type 8 17beta-HSD, type 8 17beta-hydroxysteroid dehydrogenase

ECTree

     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
                1.1.1.62 17beta-estradiol 17-dehydrogenase

Expression

Expression on EC 1.1.1.62 - 17beta-estradiol 17-dehydrogenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
application of medroxyprogestrone acetate, dydrogesterone and dienogest significantly decreases isoforms HSD17B1 and CYP19A1 expression and significantly increases isoform HSD17B2 expression. Dydrogesterone and dienogest also significantly suppress estrogen receptors ESR1 and ESR2 transcription, whereas medroxyprogestrone acetate and dydrogesterone significantly reduce mRNA levels of G protein-coupled estrogen receptor 1. Results thus suggest that in peritoneal endometriosis the beneficial effects of these progestins can be explained by lower HSD17B1 and higher HSD17B2 mRNA and protein levels, which lead to reduced local estradiol biosynthesis; application of medroxyprogestrone acetate, dydrogesterone and dienogest significantly decreases isoforms HSD17B1 and CYP19A1 expression and significantly increases isoform HSD17B2 expression. Dydrogesterone and dienogest also significantly suppress estrogen receptors ESR1 and ESR2 transcription, whereas medroxyprogestrone acetate and dydrogesterone significantly reduce mRNA levels of G protein-coupled estrogen receptor 1. Results thus suggest that in peritoneal endometriosis the beneficial effects of these progestins can be explained by lower HSD17B1 and higher HSD17B2 mRNA and protein levels, which lead to reduced local estradiol biosynthesis
-
exposure to tributyltin chloride at 100 ng Sn2+/l causes a decrease in mRNA levels in digestive gland, after one and two months, while no effect is observed in gonads
higher expression of 17beta-HSD1 mRNA is demonstrated in almost 50% of breast cancer tissues. Expression and activity of 17beta-HSD1 are significantly higher in breast cancer than in normal breast tissue
-
HSD17B4 mRNA expression levels are higher in males compared to females
-
significant increment of 17beta HSD1 immunoreactivity is found in breast cancer patients treated with aromatase inhibitor exemestane
-